Oncotelic Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

First Posted Date
2023-10-12
Last Posted Date
2024-08-13
Lead Sponsor
Oncotelic Inc.
Target Recruit Count
455
Registration Number
NCT06079346
Locations
🇺🇸

Karmanos Cancer Center, Detroit, Michigan, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2022-06-21
Last Posted Date
2024-03-15
Lead Sponsor
Oncotelic Inc.
Target Recruit Count
63
Registration Number
NCT05425576
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

First Posted Date
2021-03-16
Last Posted Date
2021-03-16
Lead Sponsor
Oncotelic Inc.
Target Recruit Count
18
Registration Number
NCT04801017
Locations
🇧🇷

Praxis Pesquisa Medica S / S Ltda, Jardim, Brazil

© Copyright 2024. All Rights Reserved by MedPath